In Practice

Is there transparency in the pricing of medicines in the South African private sector?

V Bangalee, F Suleman

Abstract


Recent investigations by the Competition Commission of South Africa (SA) of suspected excessive pricing of cancer medicines in SA by three global pharmaceutical companies have once again drawn attention to increasing medicine pricing transparency and warrant further public debate.


Authors' affiliations

V Bangalee, Discipline of Pharmaceutical Sciences, School of Health Sciences, Westville Campus, University of KwaZulu-Natal, Durban, South Africa

F Suleman, Discipline of Pharmaceutical Sciences, School of Health Sciences, Westville Campus, University of KwaZulu-Natal, Durban; and Prince Claus Chair of Development and Equity for the theme Affordable (Bio)Therapeutics for Public Health (September 2016 - September 2018), Faculty of Sciences, Utrecht University, Utrecht, The Netherlands

Full Text

PDF (89KB)

Keywords

Medicine pricing; South Africa; Price transparency

Cite this article

South African Medical Journal 2018;108(2):82-83. DOI:10.7196/SAMJ.2018.v108i2.12815

Article History

Date submitted: 2018-02-01
Date published: 2018-02-01

Article Views

Abstract views: 819
Full text views: 390

Comments on this article

*Read our policy for posting comments here